finance.yahoo.com

Karyopharm Highlights Myelofibrosis Data but Faces September Liquidity Deadline

Karyopharm Therapeutics logoKaryopharm Therapeutics
Sig4.25Sen-2.65Env0.00Soc+0.85Gov-0.60

In its Q2 earnings call on Aug. 13, Karyopharm presented myelofibrosis combination-therapy data supporting an FDA accelerated approval pathway, with an overall survival hazard ratio of 0.43. Revenue fell to $33.4 million as Menarini reimbursement ended, while the company reported a widening $67 million net loss. Cash was $65.4 million, but a $15.8 million term-loan payment is due Sept. 10, risking an event of default if no waiver or new financing arrives.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro